دورية أكاديمية
Preclinical Ultra-High Dose Rate (FLASH) Proton Radiation Therapy System for Small Animal Studies.
العنوان: | Preclinical Ultra-High Dose Rate (FLASH) Proton Radiation Therapy System for Small Animal Studies. |
---|---|
المؤلفون: | Cao N; Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington., Erickson DPJ; Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington., Ford EC; Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington., Emery RC; Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington., Kranz M; Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington., Goff P; Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington., Schwarz M; Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington., Meyer J; Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington., Wong T; Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington., Saini J; Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington., Bloch C; Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington., Stewart RD; Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington., Sandison GA; Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington., Morimoto A; Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington., DeLonais-Dick A; Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington., Shaver BA; Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington., Rengan R; Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington., Zeng J; Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington. |
المصدر: | Advances in radiation oncology [Adv Radiat Oncol] 2023 Dec 17; Vol. 9 (3), pp. 101425. Date of Electronic Publication: 2023 Dec 17 (Print Publication: 2024). |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101677247 Publication Model: eCollection Cited Medium: Print ISSN: 2452-1094 (Print) Linking ISSN: 24521094 NLM ISO Abbreviation: Adv Radiat Oncol Subsets: PubMed not MEDLINE |
أسماء مطبوعة: | Original Publication: [Philadelphia, PA] : Elsevier Inc., [2016]- |
مستخلص: | Purpose: Animal studies with ultrahigh dose-rate radiation therapy (FLASH, >40 Gy/s) preferentially spare normal tissues without sacrificing antitumor efficacy compared with conventional dose-rate radiation therapy (CONV). At the University of Washington, we developed a cyclotron-generated preclinical scattered proton beam with FLASH dose rates. We present the technical details of our FLASH radiation system and preliminary biologic results from whole pelvis radiation. Methods and Materials: A Scanditronix MC50 compact cyclotron beamline has been modified to produce a 48.7 MeV proton beam at dose rates between 0.1 and 150 Gy/s. The system produces a 6 cm diameter scattered proton beam (flat to ± 3%) at the target location. Female C57BL/6 mice 5 to 6 weeks old were used for all experiments. To study normal tissue effects in the distal colon, mice were irradiated using the entrance region of the proton beam to the whole pelvis, 18.5 Gy at different dose rates: control, CONV (0.6-1 Gy/s) and FLASH (50-80 Gy/s). Survival was monitored daily and EdU (5-ethynyl-2´-deoxyuridine) staining was performed at 24- and 96-hours postradiation. Cleaved caspase-3 staining was performed 24-hours postradiation. To study tumor control, allograft B16F10 tumors were implanted in the right flank and received 18 Gy CONV or FLASH proton radiation. Tumor growth and survival were monitored. Results: After 18.5 Gy whole pelvis radiation, survival was 100% in the control group, 0% in the CONV group, and 44% in the FLASH group ( P < .01). EdU staining showed cell proliferation was significantly higher in the FLASH versus CONV group at both 24-hours and 96-hours postradiation in the distal colon, although both radiation groups showed decreased proliferation compared with controls ( P < .05). Lower cleaved caspase-3 staining was seen in the FLASH versus conventional group postradiation ( P < .05). Comparable flank tumor control was observed in the CONV and FLASH groups. Conclusions: We present our preclinical FLASH proton radiation system and biologic results showing improved survival after whole pelvis radiation, with equivalent tumor control. Competing Interests: Juergen Meyer receives research funding from the Germany Academic Exchange Service. Ramesh Rengan receives consulting fees from AstraZeneca, Gilead Sciences, IBA. Food/beverages from Elekta, Siemens, ViewRay. Jing Zeng receives research funding and consulting/honoraria fees from AstraZeneca, Gilead Sciences, IBA, Research funding from NIH RCA258997A and Kuni Foundation. All other authors have no disclosures. (© 2023 The Author(s).) |
References: | Int J Mol Sci. 2020 Sep 05;21(18):. (PMID: 32899466) Ecancermedicalscience. 2017 Nov 30;11:785. (PMID: 29225692) Radiother Oncol. 2019 Oct;139:11-17. (PMID: 31253466) Sci Transl Med. 2014 Jul 16;6(245):245ra93. (PMID: 25031268) Phys Med Biol. 2017 Nov 21;62(24):9260-9281. (PMID: 29053105) Med Phys. 2022 Mar;49(3):2039-2054. (PMID: 34644403) Cancers (Basel). 2021 Aug 23;13(16):. (PMID: 34439398) PLoS One. 2022 Sep 16;17(9):e0274007. (PMID: 36112695) Radiat Res. 2020 Dec 1;194(6):656-664. (PMID: 32991708) Phys Med Biol. 2017 Jan 7;62(1):43-58. (PMID: 27973343) Clin Cancer Res. 2019 Jan 1;25(1):35-42. (PMID: 29875213) Neuro Oncol. 2023 May 4;25(5):927-939. (PMID: 36334265) Int J Radiat Oncol Biol Phys. 2020 Feb 1;106(2):440-448. (PMID: 31928642) Cancers (Basel). 2021 Mar 01;13(5):. (PMID: 33804336) Cancers (Basel). 2023 Apr 13;15(8):. (PMID: 37190197) Br J Radiol. 2020 Feb 01;93(1106):20190702. (PMID: 31825653) Sci Rep. 2020 Dec 10;10(1):21600. (PMID: 33303827) Oncol Lett. 2022 Oct 05;24(6):419. (PMID: 36284652) Radiother Oncol. 2017 Sep;124(3):365-369. (PMID: 28545957) Adv Radiat Oncol. 2022 Jul 02;7(6):101011. (PMID: 36092986) Adv Radiat Oncol. 2022 Nov 19;8(2):101124. (PMID: 36578276) Phys Med Biol. 2020 Dec 04;65(23):23TR03. (PMID: 32721941) Clin Cancer Res. 2022 Sep 1;28(17):3814-3823. (PMID: 35421221) |
تواريخ الأحداث: | Date Created: 20240221 Latest Revision: 20240222 |
رمز التحديث: | 20240222 |
مُعرف محوري في PubMed: | PMC10877683 |
DOI: | 10.1016/j.adro.2023.101425 |
PMID: | 38379895 |
قاعدة البيانات: | MEDLINE |
تدمد: | 2452-1094 |
---|---|
DOI: | 10.1016/j.adro.2023.101425 |